A Biodegradable Nanosuspension Locally Used for Inhibiting Postoperative Recurrence and Brain Metastasis of Breast Cancer
Source abstract
Abstract
Addressing the urgent need to prevent breast cancer postoperative recurrence and brain metastasis, Fe-metal organic framework (MOF)-coated hollow mesoporous organosilica nanoparticles (HMON) with tumor microenvironment dual-responsive degradability were prepared to encapsulate doxorubicin (DOX), formulating a tissue-adhesive nanosuspension for perioperative topical medication. This nanosuspension can not only retain the sustainably released drug in the postoperative residual tumor sites but also enhance the intracellular oxidative stress of tumors for remarkable tumor ferroptosis. Interestingly, the nanosuspension can act as an immune amplifier, which could not only stimulate DC cells to secrete chemokines for T cell recruitment but also elevate antigen exposure to facilitate the antigen presentation in lymph nodes. Thus, this nanosuspension could significantly activate antitumor immune responses in both in situ tumors and metastatic encephaloma for enhanced immunotherapy. In conjunction with the clinical PD-1 antibody, the locally administered nanosuspension could achieve an advanced therapeutic outcome for inhibiting postoperative recurrence and metastasis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Brain Metastases and Treatment · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education), Huashan Hospital, Fudan University, Shanghai 201203, China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Science and Technology Innovation Plan Laboratory Animal Research Project of Shanghai
References (32)
Show source-provided references
1. 10.1016/S0140-6736(16)31392-710.1016/S0140-6736(16)31392-7 ↗
2. 10.1038/s41568-020-0266-x10.1038/s41568-020-0266-x ↗
3. Curigliano, G.; Burstein, H. J.; Winer, E. P.; Gnant, M.; Dubsky, P.; Loibl, S.; Colleoni, M.; Regan, M. M.; Piccart-Gebhart, M.; Senn, H. J.; Thürlimann, B. St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer; St. Gallen International, 2017.
4. 10.1093/annonc/mdx30810.1093/annonc/mdx308 ↗
5. 10.1038/nrclinonc.2017.19410.1038/nrclinonc.2017.194 ↗
6. 10.1016/j.ctrv.2021.10232410.1016/j.ctrv.2021.102324 ↗
7. 10.1200/JCO.20.0339910.1200/JCO.20.03399 ↗
8. 10.1016/S0140-6736(21)01789-X10.1016/S0140-6736(21)01789-X ↗
9. Artemov D. · Cancer Res. · 2001 · 61 · 3039
10. 10.1021/ja505212y10.1021/ja505212y ↗
11. 10.1038/s41571-021-00552-710.1038/s41571-021-00552-7 ↗
12. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
13. 10.3390/cells1103032010.3390/cells11030320 ↗
14. 10.1200/JCO.21.0288510.1200/JCO.21.02885 ↗
15. 10.1016/j.ccell.2018.01.01110.1016/j.ccell.2018.01.011 ↗
16. 10.1016/j.cell.2022.03.03310.1016/j.cell.2022.03.033 ↗
17. 10.1073/pnas.122225111010.1073/pnas.1222251110 ↗
18. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
19. 10.1038/nm152310.1038/nm1523 ↗
20. 10.1016/j.jcis.2018.12.08610.1016/j.jcis.2018.12.086 ↗
21. 10.1007/s12221-020-9523-610.1007/s12221-020-9523-6 ↗
22. 10.1002/adfm.20201039010.1002/adfm.202010390 ↗
23. 10.1021/acsnano.1c0545110.1021/acsnano.1c05451 ↗
24. 10.1002/smll.20200180510.1002/smll.202001805 ↗
25. 10.1136/jitc-2021-00250810.1136/jitc-2021-002508 ↗
26. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
27. 10.1016/j.seppur.2022.12050910.1016/j.seppur.2022.120509 ↗
28. 10.1021/acsanm.8b0202310.1021/acsanm.8b02023 ↗
29. 10.1021/acsami.9b1944610.1021/acsami.9b19446 ↗
30. 10.1038/s41556-022-00881-410.1038/s41556-022-00881-4 ↗
31. 10.1002/adma.20220546210.1002/adma.202205462 ↗
32. 10.1126/sciadv.aaw608110.1126/sciadv.aaw6081 ↗